BIOCRYST PHARMACEUTICALS, INC.

(BCRX)
  Bericht
ÜbersichtKurseChartsNewsRatingsTermineUnternehmenFinanzenAnalystenschätzungenRevisionenDerivate 
ÜbersichtAlle NewsAnalystenempfehlungenAndere SprachenPressemitteilungenOffizielle PublikationenBranchen-News
Nachrichten in anderen Sprachen über BIOCRYST PHARMACEUTICALS, INC.
04.07.BioCryst Presents New Data Demonstrating Consistently Low Attack Rates Among HAE Patien..
01.07.BioCryst Presents New Data Demonstrating Consistently Low Attack Rates Among HAE Patien..
01.07.BioCryst Pharmaceuticals, Inc. Presents New Data Demonstrating Consistently Low Attack ..
23.06.BioCryst Announces ORLADEYO (berotralstat) Data to be Presented at European Academy of ..
22.06.BioCryst Announces ORLADEYO® (berotralstat) Data to be Presented at European Academy of..
22.06.BioCryst Announces ORLADEYO(R) (berotralstat) Data to be Presented at European Academy ..
10.06.BioCryst Selects Pint Pharma as Commercial Partner for ORLADEYO (berotralstat) in Latin..
09.06.BioCryst Pharmaceuticals, Inc. - FDA Grants Fast Track Designation for BioCryst's ALK-2..
09.06.BioCryst Pharmaceuticals Taps Pint Pharma as Commercial Partner for Orladeyo Drug in La..
09.06.BioCryst Selects Pint Pharma as Commercial Partner for ORLADEYO® (berotralstat) in Lati..
08.06.BioCryst's BCX9250 Secures Fast Track Designation from the US Food and Drug Administrat..
08.06.BioCryst Announces Approval of ORLADEYO (berotralstat) by Swissmedic
08.06.Biocryst Pharmaceuticals, Inc. Announces FDA Grants Fast Track Designation for ALK-2 In..
08.06.FDA Grants Fast Track Designation for BioCryst's ALK-2 Inhibitor, BCX9250
08.06.BioCryst Pharma Gets Fast Track Designation for BCX9250
07.06.BIOCRYST PHARMACEUTICALS INC : Change in Directors or Principal Officers, Submission of Ma..
07.06.BioCryst Pharmaceuticals Says Swiss Drug Regulator Approves Orladeyo to Prevent Angioed..
07.06.BioCryst Announces Approval of ORLADEYO® (berotralstat) by Swissmedic
07.06.Biocryst Pharmaceuticals, Inc. Announces Approval of Orladeyo(R) (Berotralstat) by Swis..
07.06.BioCryst Announces Health Canada has Authorized ORLADEYO (berotralstat), the Only Oral ..
06.06.BioCryst Pharmaceuticals Gets Canada's Approval of Oral Treatment to Prevent Hereditary..
06.06.BioCryst Announces Health Canada has Authorized ORLADEYO® (berotralstat), the Only Oral..
06.06.Biocryst Announces Health Canada Has Authorized Orladeyo® (Berotralstat), the Only Oral..
01.06.BioCryst to Present at Upcoming Investor Conferences
10.05.TRANSCRIPT : BioCryst Pharmaceuticals, Inc. Presents at Bank of America 2022 Healthcare Co..
09.05.BioCryst to Present at Upcoming Investor Conferences
09.05.BIOCRYST PHARMACEUTICALS INC Management's Discussion and Analysis of Financial Conditi..
06.05.BioCryst to Present at Upcoming Investor Conferences
05.05.BioCryst Reports Inducement Grants under Nasdaq Listing Rule 5635(4)
05.05.TRANSCRIPT : BioCryst Pharmaceuticals, Inc., Q1 2022 Earnings Call, May 05, 2022
05.05.Earnings Flash (BCRX) BIOCRYST PHARMACEUTICALS Reports Q1 Revenue $49.9M, vs. Street Es..
05.05.BIOCRYST : Q1 Earnings Snapshot
05.05.BIOCRYST PHARMACEUTICALS INC : Results of Operations and Financial Condition, Regulation F..
05.05.BioCryst Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended Mar..
05.05.BioCryst Reports First Quarter 2022 Financial Results and Upcoming Key Milestones
05.05.BioCryst Pharmaceuticals, Inc. Provides Revenue Guidance for the Year 2022
04.05.BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
28.04.European Medicines Agency Grants PRIME Designation to BioCryst's ALK-2 Inhibitor, BCX92..
27.04.BioCryst Pharmaceuticals' BCX9250 Drug Candidate Secures Access to EU's PRIME Program; ..
27.04.European Medicines Agency Grants PRIME Designation to BioCryst's ALK-2 Inhibitor, BCX92..
27.04.European Medicines Agency Grants PRIME Designation to BioCryst Pharmaceuticals, Inc.'s ..
21.04.BioCryst to Report First Quarter 2022 Financial Results on May 5
18.04.BioCryst Pharmaceuticals Shares Drop Midday Following Barclays Downgrade
14.04.TRANSCRIPT : BioCryst Pharmaceuticals, Inc. Presents at Needham 21st Annual Healthcare Con..
12.04.NORTH AMERICAN MORNING BRIEFING : Stocks Waver, -3-
11.04.BioCryst to Present at Upcoming Investor Conference
11.04.BIOCRYST PHARMACEUTICALS : Regulation FD Disclosure - Form 8-K
11.04.BIOCRYST PHARMACEUTICALS INC : Regulation FD Disclosure (form 8-K)
08.04.SECTOR UPDATE : Health Care Stocks Enjoy Late Uptick
08.04.Top Midday Decliners
08.04.SECTOR UPDATE : Health Care Stocks Firming in Mostly Higher Market
08.04.BioCryst Suspends Patient Enrollment in Clinical Trials for BCX9930; Shares Tumble
08.04.BIOCRYST PHARMACEUTICALS : Pauses Enrollment in BCX9930 Clinical Trials - Form 8-K
08.04.BIOCRYST PHARMACEUTICALS INC : Other Events, Financial Statements and Exhibits (form 8-K)
08.04.BioCryst Pharmaceuticals Pauses Enrollment in BCX9930 Clinical Trials, Shares Plummet 2..
08.04.BioCryst Pharmaceuticals, Inc. Pauses Enrollment in BCX9930 Clinical Trials
08.04.BioCryst Pauses Enrollment in BCX9930 Clinical Trials
05.04.BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04.04.INSIDER SELL : Biocryst Pharmaceuticals
16.03.TRANSCRIPT : BioCryst Pharmaceuticals, Inc. Presents at Barclays Global Healthcare Confere..
15.03.INSIDER SELL : Biocryst Pharmaceuticals
03.03.BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(4)
03.03.BioCryst to Present at Upcoming Investor Conferences
02.03.BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01.03.BIOCRYST PHARMACEUTICALS INC MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITI..
25.02.BioCryst Presents New Data Demonstrating Sustained Reductions in Attack Rates and Impro..
24.02.BioCryst Presents New Data Demonstrating Sustained Reductions in Attack Rates and Impro..
24.02.Biocryst Pharmaceuticals, Inc. Presents New Data Demonstrating Sustained Reductions in ..
23.02.TRANSCRIPT : BioCryst Pharmaceuticals, Inc., Q4 2021 Earnings Call, Feb 23, 2022
23.02.BIOCRYST : Q4 Earnings Snapshot
23.02.BioCryst Pharmaceuticals Reports Widened Q4 Adjusted Loss While Revenue Grows
23.02.BIOCRYST PHARMACEUTICALS : Reports Fourth Quarter and Full Year 2021 Financial Results and..
23.02.BIOCRYST PHARMACEUTICALS INC : Results of Operations and Financial Condition, Regulation F..
23.02.BioCryst Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended Decembe..
23.02.BioCryst Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended De..
1  2  3  4  5  6  7  8  9  10Weiter
Anstehende Termine für BIOCRYST PHARMACEUTICALS, INC.